Design, synthesis and antitumor activity of aromatic urea-quinazolines

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Clarke JM, Hurwitz HI. Understanding and targeting resistance to anti-angiogenic therapies. J. Gastrointest. Oncol. 4(3), 253–263 (2013).
  Medline CASGoogle Scholar
• 2. Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36(7), 422–439 (2015).
  Medline CASGoogle Scholar
• 3. Mostafa Mm El-Miligy HaaER, Marwa M Abu-Serie. Synthesis of piperazine-based thiazolidinones as VEGFR2 tyrosine kinase inhibitors inducing apoptosis. Future Med. Chem. 9(15), 1709–1729 (2017).
  Google Scholar
• 4. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 5(3), 203–220 (2007).
  Medline CASGoogle Scholar
• 5. Barbosa ML, Lima LM, Tesch R et al. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. Eur. J. Med. Chem. 71, 1–14 (2014).
  MedlineGoogle Scholar
• 6. Nakagawa T, Matsushima T, Kawano S et al. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor. Cancer Sci. 105(6), 723–730 (2014).
  Medline CASGoogle Scholar
• 7. Xi L, Zhang JQ, Liu ZC et al. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking. Org. Biomol. Chem. 11(26), 4367–4378 (2013).
  Medline CASGoogle Scholar
• 8. Zuo SJ, Zhang S, Mao S et al. Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents. Bioorg. Med. Chem. 24(2), 179–190 (2016). •• 4-anilinoquinazolines have multiple biological activities, notably as EGFR inhibitors.
  Medline CASGoogle Scholar
• 9. Simon GR, Ruckdeschel JC, Williams C et al. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control 10(5), 388–395 (2003).
  MedlineGoogle Scholar
• 10. Ishikawa T, Seto M, Banno H et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J. Med. Chem. 54(23), 8030–8050 (2011).
  Medline CASGoogle Scholar
• 11. Janmaat ML, Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 8(6), 576–586 (2003). •• The interaction between 4-anilinoquinazoline and EGFR.
  Medline CASGoogle Scholar
• 12. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am. J. Pathol. 169(5), 1875–1885 (2006).
  Medline CASGoogle Scholar
• 13. Eisen T, Joensuu H, Nathan P et al. 7141 POSTER Phase II trial of the oral multikinase inhibitor regorafenib (BAY 73-4506) as first-line therapy in patients with metastatic or unresectable renal cell carcinoma (RCC). Eur. J. Cancer 47, S517 (2011).
  Google Scholar
• 14. Jeffrey Jie LL. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 50, 409–424 (2007). •• The interaction between urea group and VEGFR-2.
  MedlineGoogle Scholar
• 15. Mctigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc. Natl Acad. Sci. USA 109(45), 18281–18289 (2012).
  Medline CASGoogle Scholar
• 16. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277(48), 46265–46272 (2002).
  Medline CASGoogle Scholar
• 17. Mowafy S, Farag NA, Abouzid KA. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors. Eur. J. Med. Chem. 61, 132–145 (2013).
  Medline CASGoogle Scholar
• 18. Vema A, Panigrahi SK, Rambabu G, Gopalakrishnan B, Sarma JaRP, Desiraju GR. Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies. Bioorg. Med. Chem. 11(21), 4643–4653 (2003).
  Medline CASGoogle Scholar
• 19. Ismail RSM, Ismail NSM, Abuserii S, Abou El Ella DA. Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents. Future J. Pharm. Sci. 2(1), 9–19 (2016).
  Google Scholar
• 20. Zhang K, Cao DY, Xue N, Shi QW, Du YM, Dong M: CN103382182 A (2013). • Synthesis methods of target compounds.
  Google Scholar
• 21. Zhang HQ, Gong FH, Ye JQ et al. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. Eur. J. Med. Chem. 125, 245–254 (2017).
  Medline CASGoogle Scholar